RCD405s dual mechanism of action distinguishes the candidate from currently available drugs for chronic obstructive pulmonary disease (COPD). It is hoped that Arcede Pharma be able to provide a more effective treatment option to the millions of people suffering from COPD and other respiratory diseases.
Last year, Arcede Pharma completed the toxicology program with RCD405, which means that the regulatory conditions to initiate clinical studies are now in place. Acting CEO Erik Magnusson is currently working, together with the board, on a strategic development plan and resolving the financing of this next step.
Mapping confirms previous preclinical results
In the preclinical work, the mechanisms of action of RCD405 have also been mapped, in order to gain a better understanding of its properties. During the autumn, the results of collaborations with research groups at both Lunds university and Karolinska Institutet, where it was found that the candidate had both an airway relaxing and anti-inflammatory effect.
Arcede has also worked together with the medical technology company Iconovo regarding the candidate's pharmacology, with the aim of being able to make dose predictions for use with Iconovo's inhalation platforms. The idea is that RCD405 will be administered via inhalation.
New results guide work forward
Now additional results are coming from preclinical studies conducted together with University of Rome Tor Vergata which confirms the results from Lund and Karolinska. RCD405 provides concentration-dependent relaxation of human bronchial tissue. According to the company, "the efficacy and potency profile against both cholinergic and histaminergic sensitivity indicates promising prospects for future clinical trials in asthma and COPD."
Erik Magnusson writes in a press release that the results demonstrate the translational effect of the drug candidate and provide valuable insights to guide future preclinical and clinical investigations in the field of respiratory medicine.
